U.S. Markets closed
  • S&P 500

    4,060.43
    +44.21 (+1.10%)
     
  • Dow 30

    33,949.41
    +205.57 (+0.61%)
     
  • Nasdaq

    11,512.41
    +199.06 (+1.76%)
     
  • Russell 2000

    1,903.06
    +12.75 (+0.67%)
     
  • Crude Oil

    81.10
    +0.95 (+1.19%)
     
  • Gold

    1,929.70
    -12.90 (-0.66%)
     
  • Silver

    24.02
    +0.08 (+0.33%)
     
  • EUR/USD

    1.0896
    -0.0024 (-0.2179%)
     
  • 10-Yr Bond

    3.4930
    +0.0310 (+0.90%)
     
  • Vix

    18.73
    -0.35 (-1.83%)
     
  • GBP/USD

    1.2403
    +0.0001 (+0.0087%)
     
  • USD/JPY

    130.1890
    +0.6800 (+0.5251%)
     
  • BTC-USD

    23,055.38
    -364.47 (-1.56%)
     
  • CMC Crypto 200

    523.89
    -3.30 (-0.63%)
     
  • FTSE 100

    7,761.11
    +16.24 (+0.21%)
     
  • Nikkei 225

    27,362.75
    -32.26 (-0.12%)
     

Sonoma Pharmaceuticals Second Quarter 2023 Earnings: US$0.33 loss per share (vs US$0.043 loss in 2Q 2022)

Sonoma Pharmaceuticals (NASDAQ:SNOA) Second Quarter 2023 Results

Key Financial Results

  • Revenue: US$3.33m (down 11% from 2Q 2022).

  • Net loss: US$1.02m (loss widened by US$917.0k from 2Q 2022).

  • US$0.33 loss per share (further deteriorated from US$0.043 loss in 2Q 2022).

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sonoma Pharmaceuticals shares are up 31% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Sonoma Pharmaceuticals has 3 warning signs we think you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here